A randomized phase 2 trial of Irinotecan/Paclitaxel versus Irinotecan/Gemcitabine in patient with stage IIIB/IV non small cell lung cancer.
Not Applicable
- Conditions
- on Small Cell Lung cancer(NSCLC)
- Registration Number
- JPRN-jRCT1080220109
- Lead Sponsor
- Yakult Honsha Co.,Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Histologically confirmed NSCLC
Neither prior chemotherapy nor prior radiotherapy
Age between 20 and 74 years old
ECOG Performance Status: 0-1
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method